Published in final edited form as:

Chemistry. 2016 May 17; 22(21): 7059–7062. doi:10.1002/chem.201600704.

Ligand-Promoted C(sp³)–H Olefination en Route to Multi-functionalized Pyrazoles**

Dr. Weibo Yang,

Department of Chemistry, The Scripps Research Institute (TSRI) 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)

Dr. Shengqing Ye,

Department of Chemistry, The Scripps Research Institute (TSRI) 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)

Yvonne Schmidt,

Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd, San Diego, CA 92121

Dean Stamos, and

Medicinal Chemistry, Vertex Pharmaceuticals, 11010 Torreyana Rd, San Diego, CA 92121

Prof. Dr. Jin-Quan Yu

Department of Chemistry, The Scripps Research Institute (TSRI) 10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)

Jin-Quan Yu: yu200@scripps.edu

Abstract

A Pd-catalyzed/N-heterocycle-directed C(sp³)–H olefination has been developed. The monoprotected amino acid ligand (MPAA) is found to significantly promote Pd-catalyzed C(sp³)–H olefination for the first time. Cu(OAc)₂ instead of Ag⁺ salts are used as the terminal oxidant. This reaction provides a useful method for the synthesis of alkylated pyrazoles.

Graphical Abstract

A pyrazole-directed C(sp³)–H olefination has been developed. The monoprotected amino acid ligands (MPAA) are found to significantly promote the reactivity in Pd-catalyzed C(sp³)–H olefination for the first time. The applicability of using this reaction for late-stage diversification of pyrazole-based complex scaffold are demonstrated.

**We gratefully acknowledge The Scripps Research Institute, Vertex Pharmaceuticals, Inc, and the NIH (NIGMS, 5R01 GM102265) for financial support and Dr. Hari Khatuya for his help in analysing crude reactions.

Correspondence to: Jin-Quan Yu, yu200@scripps.edu.

Dedicated to Professor Barry Sharpless on the occasion of his 75th birthday

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201xxxxxx>.

Keywords

pyrazole; C–H activation; olefination; amino acid ligand

Late stage alkylation of heterocycles is a significant challenge in synthesis especially in the context of medicinal chemistry. The state-of-art relies mainly on cross-coupling of heteroaryl halides with alkyl boron and zinc reagents.¹ As alkyl halide coupling partners are often incompatible with nucleophilic heterocycles, direct C–H alkylation of heterocycles remains underdeveloped with only a handful of examples documented.² Inspired by the diversity of pharmacologically active pyrazole scaffolds (Scheme 1),³ we set out to develop pyrazole-directed C(sp³)–H olefination reaction of pendant alkyl groups to deliver diverse alkylated pyrazoles from a small number of commercially available pyrazoles. The challenges associated with achieving this goal are two-fold. First, C(sp³)–H olefination is among one of the most challenging C–H functionalization processes with only two precedents to date (Scheme 2, eq 1–2).⁴ Second, pyrazole-directed C–H activation reactions,⁵ especially C(sp³)–H activation, are rare.^{5j} Herein we report the first example of Pd-catalyzed pyrazole-directed C(sp³)–H olefination using Cu(OAc)₂ as the terminal oxidant. The mono-protected amino acid ligands (MPAA) are shown to promote C(sp³)–H olefination for the first time. In contrast to previous work which reported the formation of aza-Michael cyclization products, this C(sp³)–H olefination method can provide immediate access to products with intact olefins, which can be used as substrates for additional chemistry or potentially as covalent modifiers of proteins⁶ (eq 3).

Despite the extensive studies on Pd(II)-catalyzed C(sp²)–H olefination reactions involving either electrophilic palladation or C–H insertion pathways,⁷ the translation of these methods into saturated C(sp³)–H system has been largely unsuccessful. In the two previous examples of C(sp³)–H olefination,⁴ the newly installed olefin unit further reacts with the nucleophilic directing group to give the undesired Michael cyclization products. A powerful extension of this methodology would exploit the intrinsic directing ability of a 5-membered azole ring which may avoid undesired cyclization due to ring strain. Additionally, this methodology enables late-stage functionalization of quaternary carbon centers that would have been otherwise accessed via lengthy de novo azole ring preparations. To improve the scope and efficiency of this synthetically powerful sp³ C–H olefination reaction, it is crucial to identify a suitable ligand that could promote and modulate the reactivity. We therefore turned to the two classes of ligands that have been developed to promote C–H activation, namely, MPAA⁸ and quinoline ligands.⁹ Based on the presence of multiple vectors for exploration, we selected the commercially available methyl 3-(*tert*-butyl)-1-methyl-1*H*-pyrazole-5-carboxylate (**1a**) as the model substrate. Thus, olefination of **1a** with ethyl acrylate was examined under various conditions (see Supporting Information). In the presence of 10 mol % Pd(OTf)₂(MeCN)₄ and 20 mol% ligand, the reaction proceeded to give the olefinated product **3a** in 50% yield (Table 1, entry 1). Removal of the ligand reduced the yield to 21% suggesting a beneficial role of the ligand in the reaction (entry 2). Encouraged by this observation, we screened a set of commercially available *N*-protected amino acids with different backbones (entries 3–6). The product **3a** was obtained in 60% yield when Ac-Ile-OH was used. Changing *N*-acetyl to other protecting groups resulted in significant decrease

in yields (entries 7–9). Replacement of $\text{Pd}(\text{OTf})_2(\text{MeCN})_4$ by $\text{Pd}(\text{OAc})_2$ does not affect the reaction under these conditions (entry 10). Reducing the amount of ligand to 10 mol% increased the yield to 66% (entry 11). Running the reaction under N_2 instead of air gave significantly lower yield indicating the beneficial effect of molecular O_2 (entry 12). Other Pd sources were significantly less effective (entries 13–15). During the investigation of different oxidants, we found that less expensive oxidant $\text{Cu}(\text{OAc})_2$ also afforded the product in 37% yield (entry 19). Further examination of this reaction reveals that the combination of $\text{Cu}(\text{OAc})_2$ with O_2 decomposes starting material. Further exploration of impact of oxidants on the reaction revealed that the use of $\text{Cu}(\text{OAc})_2$ as the sole oxidant under N_2 improves the yield to 76% (entry 20). Under the optimized conditions, omission of the ligand reduced the yield to 35% confirming the beneficial ligand effect in this $\text{C}(\text{sp}^3)\text{--H}$ olefination reaction (entry 21).

We next examined the scope of pyrazoles for this ligand-promoted $\text{C}(\text{sp}^3)\text{--H}$ olefination. This catalytic system can tolerate pyrazole esters, pyrazole amides, as well as simple pyrazoles (**3a–3c**). Both electron-donating and electron-withdrawing substituents at the 4-position of the pyrazole ring afford the corresponding products (**3d–3f**) in good yields (65–71%). Other tertiary alkyls¹⁰ at the 3-positions are also reactive (**3g–3i**), although secondary and primary alkyls are not reactive under current conditions. However, functional groups on the tertiary alkyls including acetate and methoxyl are compatible (**3j**, **3k**). Interestingly, the fused tricyclic 4,5-dihydro-2*H*-benzo[*e*]indazole prepared from our previous C–H activation cascade^{5j} also gives the product **3l**, albeit in lower yield (37%). The reduced reactivity of **1l** is likely due to geometric constraints hindering the formation of the desired co-planar transition state. Successful application of $\text{C}(\text{sp}^3)\text{--H}$ olefination on pharmaceutically relevant benzo[*d*]oxazole, pyrazolo[1,5-*a*]pyridine scaffolds in the presence of additional polar functionality proceeds to give the desired products (**3m–3n**). To the best of our knowledge, these heterocycles have not been used to direct C–H activation. To further demonstrate the potential utility of this reaction, olefination of the highly functionalized pyrazole scaffold **1o** proceeded in good yield (64%) with no obvious interference of either the nitro or carbamate groups on the reaction.

With respect to the olefin coupling partners, α,β -unsaturated ketones, and aldehydes are reactive, albeit giving lower yields (**3p–3r**). These products have higher reactivity as Michael acceptors which may offer unique opportunities as covalent ligands of biologically interesting proteins.¹¹

On the basis of our previous mechanistic studies, a putative catalytic cycle is proposed for the pyrazole-directed $\text{C}(\text{sp}^3)\text{--H}$ Heck-type olefination (Scheme 3). The pyrazole directs $\text{C}(\text{sp}^3)\text{--H}$ activation to form 5-membered palladacycle intermediate **A**. Subsequent migratory insertion of **A** gives the olefinated product **3**. The Pd(0) formed from the β -hydride elimination and reductive elimination steps is oxidized by the Cu(II) oxidant to close the catalytic cycle.

In conclusion, a pyrazole-directed $\text{C}(\text{sp}^3)\text{--H}$ olefination has been developed for the first time. Our investigations revealed that mono-protected amino acid (MPAA) ligands are found

to promote C(sp³)-H olefination. The transformation has proven to be tolerant to a wide variety of functional groups thus enabling late stage diversification of candidate scaffolds.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. a) Molander GA, Wisniewski SR. J Am Chem Soc. 2012; 134:16856. [PubMed: 23025482] b) Pompeo M, Froese RDJ, Hadei N, Organ MG. Angew Chem Int Ed. 2012; 51:11354.c) Atwater B, Chandrasoma N, Mitchell D, Rodriguez MJ, Pompeo M, Froese RDJ, Organ MG. Angew Chem Int Ed. 2015; 54:9502.d) Han C, Buchwald SL. J Am Chem Soc. 2009; 131:7532. [PubMed: 19441851] e) Yang Y, Niedermann K, Han C, Buchwald SL. Org Lett. 2014; 16:4638. [PubMed: 25153332]
2. a) Ackermann L. Chem Commun. 2010; 46:4866.b) Tamura R, Yamada Y, Nakao Y, Hiyama T. Angew Chem Int Ed. 2012; 51:5679.c) Wu X, See JWT, Xu K, Hirao H, Roger J, Hierso JC, Zhou J. Angew Chem Int Ed. 2014; 53:13573.d) Xiao B, Liu ZJ, Liu L, Fu Y. J Am Chem Soc. 2013; 135:616. [PubMed: 23282325]
3. a) Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. J Med Chem. 1997; 40:1347. [PubMed: 9135032] b) de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ. J Med Chem. 2006; 49:3332. [PubMed: 16722652] c) Mousseau JJ, Bull JA, Ladd CL, Fortier A, Roman DS, Charette AB. J Org Chem. 2011; 76:8243. [PubMed: 21902233]
4. a) Wasa M, Engle KM, Yu JQ. J Am Chem Soc. 2010; 132:3680. [PubMed: 20187642] b) Stowers KJ, Fortner KC, Sanford MS. J Am Chem Soc. 2011; 133:6541. [PubMed: 21476513] c) Li S, Chen G, Feng C-G, Gong W, Yu J-Q. J Am Chem Soc. 2014; 136:5267. [PubMed: 24666182]
5. a) Asaumi T, Matsuo T, Fukuyama T, Ie Y, Kakiuchi F, Chatani N. J Org Chem. 2004; 69:4433. [PubMed: 15202898] b) Wang H, Schröder N, Glorius F. Angew Chem. 2013; 125:5495.Angew Chem Int Ed. 2013; 52:5386.c) Xie F, Qi Z, Yu S, Li X. J Am Chem Soc. 2014; 136:4780. [PubMed: 24593822] d) Gong TJ, Xiao B, Cheng WM, Su W, Xu J, Liu ZJ, Liu L, Fu Y. J Am Chem Soc. 2013; 135:10630. [PubMed: 23822812] e) Ackermann L, Althammer A, Born R. Angew Chem. 2006; 118:2681.Angew Chem Int Ed. 2006; 45:2619.f) Desai LV, Stowers KJ, Sanford MS. J Am Chem Soc. 2008; 130:13285. [PubMed: 18781752] g) Schinkel M, Marek I, Ackermann L. Angew Chem. 2013; 125:4069.Angew Chem Int Ed. 2013; 52:3977.h) Muralirajan K, Parthasarathy K, Cheng CH. Org Lett. 2012; 14:4262. [PubMed: 22873354] i) Hashimoto Y, Hirano K, Satoh T, Kakiuchi F, Miura M. J Org Chem. 2013; 78:638. [PubMed: 23237055] j) Yang W, Ye S, Fanning D, Coon T, Schmidt Y, Krenitsky P, Stamos D, Yu JQ. Angew Chem. 2015; 127:2531.Angew Chem Int Ed. 2015; 54:2501.
6. a) Xu S, Xu T, Zhang L, Zhang Z, Luo J, Liu Y, Lu X, Tu Z, Ren X, Ding K. J Med Chem. 2013; 56:8803. [PubMed: 24124898] b) Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Li H. J Med Chem. 2013; 56:7821. [PubMed: 24053674]
7. Yeung CS, Dong VM. Chem Rev. 2011; 111:1215. [PubMed: 21391561]
8. For selected examples of Pd(II)/MPAA catalyzed C-H activation, see: Engle KM, Yu JQ. J Org Chem. 2013; 78:8927. [PubMed: 23565982] Dai HX, Li G, Zhang XG, Stepan AF, Yu JQ. J Am Chem Soc. 2013; 135:7567. [PubMed: 23614807] Engle KM, Wang DH, Yu JQ. J Am Chem Soc. 2010; 132:14137. [PubMed: 20853838] Wang DH, Engle KM, Shi BF, Yu JQ. Science. 2010; 327:315. [PubMed: 19965380] Shi BF, Maugel N, Zhang YH, Yu JQ. Angew Chem Int Ed. 2008; 47:4882.Gao DW, Shi YC, Gu Q, Zhao ZL, You SL. J Am Chem Soc. 2013; 135:86. [PubMed: 23253097] Chan KSL, Fu HY, Yu JQ. J Am Chem Soc. 2015; 137:204.Chan KSL, Wasa M, Chu L, Laforteza BN, Miura M, Yu JQ. Nat Chem. 2014; 6:146. [PubMed: 24451591]
9. For selected examples of Pd(II)/quinoline ligands catalyzed C-H activation, see: Shen PX, Wang XC, Wang P, Zhu RY, Yu JQ. J Am Chem Soc. 2015; 137:11574. [PubMed: 26313012] Zhu RY,

- Tanaka K, Li GC, He J, Fu HY, Li SH, Yu JQ. J Am Chem Soc. 2015; 137:7067. [PubMed: 26001406] He J, Takise R, Fu H, Yu JQ. J Am Chem Soc. 2015; 137:4618. [PubMed: 25822198] He J, Li S, Deng Y, Fu H, Laforteza BN, Spangler JE, Homs A, Yu JQ. Science. 2014; 343:1216. [PubMed: 24626923]
10. a) Janody S, Jazzar R, Comte A, Holstein P, Vors J-P, Ford MJ, Baudoin Olivier. Chem Eur J. 2014; 20:11084. [PubMed: 25069403] b) Rousseaux S, Davi M, Sofack-Kreutzer J, Pierre C, Kefalidis CE, Clot E, Fagnou K, Baudoin O. J Am Chem Soc. 2010; 132:10706. [PubMed: 20681703] c) Liu YJ, Zhang ZZ, Yan SY, Liu YH, Shi BF. Chem Commun. 2015; 51:7899.
11. Krishnan S, Miller RM, Tian B, Mullins RD, Jacobson MP, Taunton J. J Am Chem Soc. 2014; 136:12624. [PubMed: 25153195]

Scheme 1.
Biologically active pyrazoles and pyrazolo[1,5-*a*]pyridines.

This work: MPAA ligand promoted sp^3 C-H olefination

Scheme 2.
Pd-catalyzed sp^3 C-H olefination.

Scheme 3.
Proposed catalytic pathway.

Table 1Optimization studies of Pd-catalyzed C(sp³)-H olefination.

Entry ^[a]	Catalyst	Ligand	Oxidant	Yield
1	Pd(OTf) ₂ (MeCN) ₄	Ac-Leu-OH	AgOAc	50
2	Pd(OTf) ₂ (MeCN) ₄	-	AgOAc	21
3	Pd(OTf) ₂ (MeCN) ₄	Ac-Ala-OH	AgOAc	45
4	Pd(OTf) ₂ (MeCN) ₄	Ac-Val-OH	AgOAc	49
5	Pd(OTf) ₂ (MeCN) ₄	Ac-Gly-OH	AgOAc	43
6	Pd(OTf)₂(MeCN)₄	Ac-Ile-OH	AgOAc	60
7	Pd(OTf) ₂ (MeCN) ₄	Boc-Ile-OH	AgOAc	30
8	Pd(OTf) ₂ (MeCN) ₄	Fmoc-Ile-OH	AgOAc	26
9	Pd(OTf) ₂ (MeCN) ₄	For-Ile-OH	AgOAc	31
10	Pd(OAc) ₂	Ac-Ile-OH	AgOAc	62
11 ^b	Pd(OAc) ₂	Ac-Ile-OH	AgOAc	66
12 ^{b,c}	Pd(OAc) ₂	Ac-Ile-OH	AgOAc	38
13 ^b	Pd(TFA) ₂	Ac-Ile-OH	AgOAc	41
14 ^b	Pd(acac) ₂	Ac-Ile-OH	AgOAc	26
15 ^b	PdCl ₂	Ac-Ile-OH	AgOAc	<5
16 ^b	Pd(OAc) ₂	Ac-Ile-OH	AgNO ₃	32
17 ^b	Pd(OAc) ₂	Ac-Ile-OH	K ₂ S ₂ O ₈	21
18 ^b	Pd(OAc) ₂	Ac-Ile-OH	BQ	16%
19 ^b	Pd(OAc) ₂	Ac-Ile-OH	Cu(OAc) ₂	37
20^{b,c}	Pd(OAc)₂	Ac-Ile-OH	Cu(OAc)₂	76
21 ^{b,c}	Pd(OAc) ₂	-	Cu(OAc) ₂	35

Reaction conditions:

^a pyrazole ester **1a** (0.05 mmol), ethyl acrylate (0.30 mmol), Pd catalyst (10 mol%), DCE:HFIP (9:1, 0.5 mL). All the reactions are carried out at 100 °C for 24 h. Yields were determined by the ¹H NMR using CH₂Br₂ as the internal standard.

^b 10 mol% ligand is used.

^c The reaction is performed in N₂.

Table 2

Scope of substrates in Pd-catalyzed C(sp³)-H olefination.

Reaction conditions: heterocycles **1** (0.1 mmol), ethyl acrylate (0.60 mmol), Pd catalyst (10 mol%), ligand (10 mol%), DCE:HFIP (9:1, 1.0 mL). All the reactions were carried out at 100 °C for 24 h. All the yields were isolated yields.

Table 3Scope of olefins in Pd-catalyzed C(sp³)-H olefination^a.

Reaction conditions: ^aReaction conditions: heterocycles **1a** (0.1 mmol), olefins (0.60 mmol), Pd(OAc)₂ (10 mol%, **3r**^b 15 mol%), ligand (10 mol %), DCE:HFIP (9:1, 1.0 mL). All the reactions were carried out at 100 °C for 24 h. All the yields were isolated yields.